HL7 FHIR Implementation Guide: Common Terminology Criteria (CTC) Adverse Events Release 1 - DRAFT
0.0.1 - DRAFT United States of America flag

HL7 FHIR Implementation Guide: Common Terminology Criteria (CTC) Adverse Events Release 1 - DRAFT, published by HL7 International Clinical Interoperability Council. This guide is not an authorized publication; it is the continuous build for version 0.0.1 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/standardhealth/fsh-ae/ and changes regularly. See the Directory of published versions

: medrequest-doxorubicin-persona-2 - JSON Representation

Raw json | Download


{
  "resourceType" : "MedicationRequest",
  "id" : "medrequest-doxorubicin-persona-2",
  "meta" : {
    "profile" : [
      🔗 "http://hl7.org/fhir/us/mcode/StructureDefinition/mcode-cancer-related-medication-request"
    ]
  },
  "text" : {
    "status" : "extensions",
    "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p><b>Generated Narrative: MedicationRequest</b><a name=\"medrequest-doxorubicin-persona-2\"> </a></p><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">Resource MedicationRequest &quot;medrequest-doxorubicin-persona-2&quot; </p><p style=\"margin-bottom: 0px\">Profile: <a href=\"http://hl7.org/fhir/us/mcode/2021May/StructureDefinition-mcode-cancer-related-medication-request.html\">Cancer-Related Medication Request</a></p></div><p><b>Treatment Intent</b>: Curative - procedure intent (qualifier value) <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"https://browser.ihtsdotools.org/\">SNOMED CT</a>#373808002)</span></p><p><b>status</b>: active</p><p><b>intent</b>: order</p><p><b>category</b>: Outpatient <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://terminology.hl7.org/5.3.0/CodeSystem-medicationrequest-category.html\">MedicationRequest Category Codes</a>#outpatient)</span></p><p><b>medication</b>: DOXOrubicin <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://terminology.hl7.org/5.3.0/CodeSystem-v3-rxNorm.html\">RxNorm</a>#3639)</span></p><p><b>subject</b>: <a href=\"Patient-PatientPersona2.html\">Patient/PatientPersona2</a> &quot; C.&quot;</p><p><b>authoredOn</b>: 2020-10-06</p><p><b>requester</b>: <a href=\"Practitioner-us-core-practitioner-owen-oncologist.html\">Practitioner/us-core-practitioner-owen-oncologist</a> &quot; ONCOLOGIST&quot;</p><p><b>reasonReference</b>: <a href=\"Condition-primary-cancer-condition-persona-2.html\">Condition/primary-cancer-condition-persona-2</a></p><blockquote><p><b>dosageInstruction</b></p><p><b>text</b>: doxorubicin (60 mg/m² IV)</p><p><b>timing</b>: Starting 2018-04-01, Once</p><p><b>route</b>: Intravenous route (qualifier value) <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"https://browser.ihtsdotools.org/\">SNOMED CT</a>#47625008)</span></p><blockquote><p><b>doseAndRate</b></p></blockquote><p><b>maxDosePerPeriod</b>: 1/3 week<span style=\"background: LightGoldenRodYellow\"> (Details: UCUM code wk = 'wk')</span></p></blockquote></div>"
  },
  "extension" : [
    {
      "url" : "http://hl7.org/fhir/us/mcode/StructureDefinition/mcode-treatment-intent",
      "valueCodeableConcept" : {
        "coding" : [
          {
            "system" : "http://snomed.info/sct",
            "code" : "373808002",
            "display" : "Curative - procedure intent (qualifier value)"
          }
        ]
      }
    }
  ],
  "status" : "active",
  "intent" : "order",
  "category" : [
    {
      "coding" : [
        {
          "system" : "http://terminology.hl7.org/CodeSystem/medicationrequest-category",
          "code" : "outpatient"
        }
      ]
    }
  ],
  "medicationCodeableConcept" : {
    "coding" : [
      {
        "system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
        "code" : "3639",
        "display" : "DOXOrubicin"
      }
    ]
  },
  "subject" : {
    🔗 "reference" : "Patient/PatientPersona2"
  },
  "authoredOn" : "2020-10-06",
  "requester" : {
    🔗 "reference" : "Practitioner/us-core-practitioner-owen-oncologist"
  },
  "reasonReference" : [
    {
      🔗 "reference" : "Condition/primary-cancer-condition-persona-2"
    }
  ],
  "dosageInstruction" : [
    {
      "text" : "doxorubicin (60 mg/m² IV)",
      "timing" : {
        "repeat" : {
          "boundsPeriod" : {
            "start" : "2018-04-01"
          }
        }
      },
      "route" : {
        "coding" : [
          {
            "system" : "http://snomed.info/sct",
            "code" : "47625008",
            "display" : "Intravenous route (qualifier value)"
          }
        ]
      },
      "doseAndRate" : [
        {
          "rateQuantity" : {
            "value" : 60,
            "unit" : "mg/m2",
            "system" : "http://unitsofmeasure.org",
            "code" : "mg/m2"
          }
        }
      ],
      "maxDosePerPeriod" : {
        "numerator" : {
          "value" : 1
        },
        "denominator" : {
          "value" : 3,
          "unit" : "week",
          "system" : "http://unitsofmeasure.org",
          "code" : "wk"
        }
      }
    }
  ]
}